REVIEW ARTICLE Am. J. PharmTech Res. 2026; 16(03) ISSN: 2249-3387

AMERICAN JOURNAL OF PHARMTECH RESEARCH
Journal home page: http://www.ajptr.com/

Carvedilol Microspheres: A Review of Formulation Strategies, Polymer Applications, and Drug Release Engineering

Anupama Chaturvedi*, Deepak Marothia
Department of Pharmaceutics, Bhupal Nobles' Institute of Pharmaceutical Sciences, Bhupal Nobles' University, Udaipur, Rajasthan 313001, India

ABSTRACT

Among the drugs used in long-term cardiovascular management, carvedilol occupies a special position owing to its combined non-selective beta-blockade and alpha-1 receptor antagonism. However, turning this pharmacological advantage into consistent clinical benefit is not straightforward. The molecule belongs to BCS Class II, meaning it crosses biological membranes readily but barely dissolves in physiological fluids. On top of that, extensive hepatic extraction during the first pass through the liver trims oral bioavailability to somewhere between 25 and 35 percent, and an elimination half-life of only 6 to 10 hours forces patients to take the drug multiple times a day. Together, these characteristics create the conditions for erratic plasma concentrations, missed doses, and avoidable side effects. Encapsulating carvedilol within polymer-matrix microspheres is a strategy with growing experimental support: the polymer network acts as a physical throttle on drug escape, stretching the release window well beyond what any immediate-release tablet can offer. This article brings together evidence published between 2016 and 2025 on how microsphere formulations of carvedilol are built, what polymers are chosen and why, how the finished particles are tested, and what the most informative recent studies have found. Across this body of work, entrapment efficiencies consistently exceed 75 percent when formulation conditions are properly optimized, and release profiles extending to 12 hours or beyond are regularly achieved. Floating, pH-sensitive, and mucoadhesive variants each address specific absorption or tolerability concerns, broadening the design toolbox available to formulators.

Keywords: carvedilol; microspheres; controlled-release oral delivery; ethyl cellulose; HPMC; floating microspheres; bioavailability enhancement; hypertension; polymer matrix

*Corresponding Author Name: Anupama Chaturvedi

Received 15 May 2026, Accepted 27 May 2026

Please cite this article as: Chaturvedi A *et al.*, Carvedilol Microspheres: A Review of Formulation Strategies, Polymer Applications, and Drug Release Engineering. American Journal of PharmTech Research 2026.

INTRODUCTION

Hypertension and heart failure together account for a disproportionate share of cardiovascular mortality, and their treatment relies on molecules that must be present at adequate concentrations in the bloodstream around the clock. Carvedilol fits this clinical need from a pharmacodynamic perspective: it simultaneously reduces the adrenergic drive on the heart and relaxes peripheral resistance vessels, a combination that translates into haemodynamic and survival advantages documented in large randomized trials.[1] What limits its value in practice is not its receptor pharmacology but its behaviour as an orally administered molecule.

Carvedilol's aqueous solubility is negligible under intestinal pH conditions, placing it squarely in BCS Class II. Once absorbed across the gut wall, a large fraction is intercepted by liver enzymes before it reaches the general circulation, with the result that only a quarter to a third of each dose actually becomes available to act on target tissues.[2,3] Because the drug also clears from the body relatively quickly — the half-life sits in the six to ten hour range — maintaining steady-state therapeutic concentrations with a once-daily conventional tablet is simply not achievable, and twice- or thrice-daily regimens become necessary.[3] For patients already carrying a burden of multiple medications, this additional demand on adherence carries real clinical risk.

Pharmaceutical microencapsulation offers a way to rewrite the drug's absorption story. When carvedilol is dispersed within a polymer matrix and the mixture is fashioned into spherical particles of one to one thousand micrometres, the polymer acts as a physical retardant — drug molecules must navigate a tortuous path through the matrix before they reach the dissolution medium, and this slows release in a controllable, reproducible manner.[4,5] The body then absorbs the drug gradually over many hours rather than in one rapid pulse, flattening the peaks that cause side effects and eliminating the troughs that leave patients undertreated between doses.

Research into carvedilol microspheres has accelerated markedly since 2016, with investigators testing ethyl cellulose walls, gastric-retentive floating designs, enteric pH-triggered systems, and mucoadhesive surfaces, among other approaches.[6] This article reviews that body of work systematically: it begins with the drug's own properties, moves through microsphere classification and manufacturing, examines the polymers most commonly chosen, describes the evaluation framework, and concludes with a critical synthesis of recent experimental findings and a forward look at where the field should go next.

CARVEDILOL: PROPERTIES AND PHARMACOKINETICS

Molecular and Physical Characteristics

Chemically, carvedilol is a racemic mixture with the molecular formula C24H26N2O4 and a molar mass of 406.5 g/mol (CAS registry number 72956-09-3). At room temperature it presents as a fine white to off-white powder that is practically insoluble in water but dissolves without difficulty in dichloromethane, methanol, and dimethyl sulfoxide.[7] Its partition coefficient (log P approximately 3.16) indicates strong lipophilicity, which explains both its efficient passive membrane permeation and its tendency to accumulate in tissues rather than remain in the aqueous plasma compartment. Solubility is sensitive to pH and climbs appreciably in acidic conditions, a property that formulation scientists exploit when designing gastric-retentive dosage forms.

Two solid-state polymorphs have been characterized. Polymorph I is thermodynamically more stable with a melting onset around 123 to 126 degrees Celsius; Polymorph II is metastable and melts between 114 and 115 degrees Celsius. Neither form readily absorbs atmospheric moisture, so hygroscopic degradation during manufacture and storage is not a primary concern. The basic pKa of approximately 7.8 means the molecule is partly ionized under physiological intestinal pH, which slightly tempers its intrinsic membrane permeability. [7,8]

Receptor Pharmacology

The drug's therapeutic portfolio rests on blockade of three adrenoceptor subtypes: beta-1 receptors in the heart, beta-2 receptors in the vasculature and bronchi, and alpha-1 receptors on peripheral resistance arteries. Blocking cardiac beta-1 receptors decreases both heart rate and the force of contraction, curtailing the heart's oxygen consumption and relieving the workload on a failing ventricle. Simultaneous alpha-1 blockade relaxes arteriolar smooth muscle, cutting afterload — an effect that, unlike pure vasodilation, is not accompanied by compensatory tachycardia.[1] Beyond these adrenergic effects, carvedilol also scavenges free radicals, inhibits programmed cardiomyocyte death, and suppresses fibroblast proliferation, actions that collectively promote structural remodelling of the heart after injury.[9]

Pharmacokinetic Profile and Its Formulation Implications

Following an oral dose, the drug is absorbed from the proximal small intestine and reaches maximum plasma concentrations within one to two hours. The rate of absorption slows when the tablet is taken with a meal, although the total absorbed amount changes little.[10] The absolute bioavailability figure of 25 to 35 percent reflects the degree to which the liver extracts and metabolises the drug before it enters the systemic circulation. This first-pass extraction is mediated predominantly by CYP2D6 and CYP2C9, producing three hydroxylated metabolites with varying degrees of pharmacological activity; one of these metabolites is roughly 13-fold more potent at beta receptors than the parent compound itself.[11] Plasma protein binding exceeds 98 percent and the apparent volume of distribution is approximately 115 litres, both figures consistent with the drug's lipophilicity and its tendency to partition into peripheral tissues.

Elimination proceeds mainly via bile and faeces, with urinary excretion accounting for only about 16 percent of the dose. The terminal half-life of six to ten hours means that with conventional formulations, twice-daily dosing at minimum is required to keep plasma concentrations within the therapeutic window throughout a 24-hour period.[3,10,11] A microsphere-based controlled-release system can address three of these limitations simultaneously: it extends the absorption phase to match the drug's elimination rate, it can improve bioavailability by presenting a more gradual concentration gradient that partially saturates first-pass enzymes without overwhelming them, and it can lengthen the dose interval to once daily — the single most impactful change for improving long-term adherence in a chronically treated patient population.[12]

MICROSPHERE TYPES AND THEIR RELEVANCE TO CARVEDILOL

In pharmaceutical terminology, a microsphere is a solid, roughly spherical particle with a diameter somewhere in the one to one thousand micrometre range, in which the active substance is either dissolved in or uniformly dispersed throughout a continuous polymer matrix. This structure differs from a microcapsule, where a defined membrane encloses a central drug reservoir. The matrix architecture is generally advantageous for hydrophobic drugs such as carvedilol because the drug partitions naturally into the lipophilic polymer phase during manufacture, facilitating efficient entrapment.[13]

Several design variants have been explored specifically for this drug. Bioadhesive particles carry mucoadhesive polymers on their surfaces — chitosan and carbopol are common choices — whose functional groups form non-covalent bonds with the mucin layer coating the gastrointestinal epithelium.[14] By anchoring the microsphere to the mucosal surface, transit through the gut is slowed and the time available for drug absorption from the target segment is extended. Floating microspheres, sometimes called microballoons, are engineered to be less dense than gastric contents so they stay suspended at the top of the gastric fluid pool rather than emptying into the intestine.[15,16] For carvedilol, whose acid-environment solubility is much better than its intestinal solubility, keeping the dosage form in the stomach for longer can meaningfully increase the dissolved drug fraction presented to the absorptive epithelium of the proximal small bowel.

pH-triggered systems use polymers that remain insoluble in the acidic stomach and dissolve only when the pH climbs above a threshold value in the intestine. This approach sidesteps any risk of gastric irritation and is particularly useful when the drug's solubility profile makes intestinal delivery preferable.[16] Biodegradable microspheres made from aliphatic polyesters such as PLGA degrade through hydrolysis of ester bonds at a rate that depends on molecular weight and co-polymer composition, providing programmable drug release without accumulation of non-degradable residues.[17] Magnetic microspheres containing iron oxide particles can be steered to specific anatomical locations using external magnetic fields; while cardiovascular applications remain experimental, the technology illustrates how microsphere engineering continues to evolve.[18]

MANUFACTURING METHODS

Emulsion Solvent Evaporation

Of all the techniques for making carvedilol microspheres, the oil-in-water emulsion solvent evaporation route is by far the most commonly used, and the reasons are practical. Dissolving the drug alongside the chosen polymer in a volatile water-immiscible solvent — most often dichloromethane, sometimes blended with ethanol — is straightforward because carvedilol's lipophilicity makes it highly soluble in organic media. When this organic solution is poured or syringed into a stirred aqueous bath containing a surfactant such as polyvinyl alcohol, the mechanical shear breaks it into countless microscopic droplets. The surfactant molecules adsorb at the interface of each droplet, preventing neighbouring droplets from coalescing. Over the following three to four hours, the organic solvent gradually diffuses across the interface and evaporates from the aqueous surface, and the polymer precipitates progressively within each droplet until a solid sphere has formed. The particles are then collected by filtration, rinsed free of surface surfactant residues, and dried.[19]

Every step in this sequence has levers the formulator can adjust. Stirrer speed directly sets the droplet size and therefore the final particle diameter. Raising polymer concentration thickens the matrix wall and both slows diffusion of drug molecules through it and raises the entrapment efficiency. Surfactant concentration must be balanced: too little and the emulsion collapses; too much and drug partitions out into the aqueous phase before the particles solidify. The temperature of the aqueous phase affects the evaporation rate and hence the porosity of the final particle wall. Kumar et al. in 2022 illustrated these principles by showing that Eudragit RS100 microballoons prepared at a drug-to-polymer mass ratio of 1:3 captured more than 85 percent of the loaded carvedilol and floated for over 12 hours with more than 80 percent of the particles remaining buoyant.[20]

Spray Drying

Spray drying converts a liquid mixture directly into a dry powder in a single operation. A solution or suspension of drug and polymer is fed into the machine, atomized through a nozzle into a current of hot air, and the solvent evaporates almost instantaneously as the droplets travel through the drying chamber, leaving dry microspheres that are collected by a cyclone separator.[21] The method scales easily and produces particles with a narrow size distribution, but it requires that the drug withstand the inlet air temperature, which for carvedilol should be kept comfortably below 150 degrees Celsius. Al-Kassas and colleagues in 2019 applied spray drying to chitosan-carvedilol mixtures and produced smooth, nearly spherical particles that released drug in a sustained fashion over eight hours in simulated stomach contents.[22]

Ionotropic Gelation

Ionotropic gelation is particularly suited to natural polysaccharide polymers and avoids organic solvents entirely. In the version used most for carvedilol, sodium alginate and the drug are dissolved together in water, and this solution is extruded through a syringe or nozzle as droplets falling into a bath of calcium chloride solution. Divalent calcium ions rapidly penetrate each droplet and crosslink the carboxylate groups on adjacent alginate chains, forming a three-dimensional network that traps the drug within a firm gel bead.[23] The tightness of the network — and therefore how quickly the drug can diffuse out — can be adjusted by changing the alginate concentration, the calcium chloride concentration, and the residence time in the crosslinking bath. When gas-generating agents such as sodium bicarbonate are included, the beads trap gas pockets during gelation and become buoyant. Sabale and coworkers in 2023 used a statistical factorial design to find the optimal combination of alginate and pectin concentrations, demonstrating beads that floated without a lag period and released drug uniformly in simulated gastric fluid for 12 hours.[24]

Coacervation and Solvent Extraction

Coacervation causes the polymer to spontaneously deposit around drug particles by reducing its solubility in the organic phase through addition of a competing polymer, a non-solvent, or a change in temperature. The polymer-rich liquid phase — the coacervate — wraps around the dispersed drug and is then hardened by crosslinking or solvent removal. The technique yields reservoir-style particles but demands careful control of precipitation kinetics.[19] Solvent extraction speeds up particle hardening in ESE-derived formulations by transferring the organic solvent into a large volume of water rather than waiting for it to evaporate. This speeds production and can reduce particle porosity, though the outcome depends on the solvent-water miscibility ratio and bath temperature.[25]

POLYMER SELECTION AND ROLES

Every aspect of microsphere performance — how much drug is captured, how fast it escapes, how the particles behave in the gut, and whether they remain stable on the shelf — is governed more by polymer chemistry than by any other single design variable. Before a polymer can be considered for pharmaceutical use, it must clear a demanding set of criteria: neither the polymer itself nor anything it breaks down into may be toxic at the amounts reaching systemic circulation; it must be soluble or dispersible in media compatible with the chosen manufacturing method; its molecular architecture must allow the drug payload to be trapped efficiently; its behaviour in biological fluids must be predictable and reproducible; and it must have a track record of regulatory acceptance.[26]

Ethyl cellulose sits at the centre of most carvedilol sustained-release microsphere formulations because its properties match carvedilol's needs almost perfectly. The polymer is water-insoluble across the entire physiological pH range, which means the rate of drug diffusion through the matrix wall is governed by concentration gradient and diffusion coefficient rather than by where in the gut the particle happens to be. It dissolves readily in dichloromethane and ethanol, the solvents used in ESE, and it forms mechanically robust films.[27] The drawback of a pure ethyl cellulose wall is that at high polymer concentrations the matrix can become so dense that drug release is slow and incomplete — a problem remedied by blending in a hydrophilic partner. HPMC K100M fills this role: when the microsphere encounters water, the HPMC absorbs it, swells into a gel, and eventually dissolves, opening pores through which drug molecules can exit at a rate controlled by adjusting the EC:HPMC ratio.[28] Sharma et al. in 2023 demonstrated the potency of this combination, with HPMC K100M-based matrices releasing 98 percent of their carvedilol payload in a controlled fashion over more than 12 hours while simultaneously staying buoyant in simulated gastric contents.[29]

Eudragit RS100 has earned a place in carvedilol microsphere research because its quaternary ammonium substituents give it a small but definite permeability to water and dissolved solutes, even though the polymer as a whole is insoluble at all gut pH values. This permeability can be tuned by mixing RS100 with RL100, which carries more of the ammonium groups and therefore allows drug to diffuse through it more freely. The result is a reliable, pH-independent sustained release that does not accelerate in the acid stomach or decelerate in the alkaline intestine.[20] Eudragit S100 operates differently: a threshold of pH 7.0 triggers its dissolution, enabling the formulator to protect carvedilol completely from the acidic gastric environment and deploy it in the lower intestine where the pH rises above that threshold. Sahoo and colleagues in 2020 exploited this property to produce microspheres that released nothing measurable in the two-hour gastric phase and then dissolved completely at intestinal pH.[30]

Sodium alginate and chitosan represent the natural polymer side of the toolbox. Alginate's rapid and gentle crosslinking response to calcium ions makes it easy to form beads under ambient, solvent-free conditions; incorporating gas-generating agents during bead formation gives particles that float on gastric contents for extended periods.[24,31] Chitosan's polycationic character creates strong electrostatic interactions with the negatively charged mucin molecules that coat the gut wall, giving mucoadhesive properties that extend the residence time of the microspheres in the absorptive zone.[22] Table 1 presents a condensed comparison of these polymers.

Table 1: Polymers Employed in Carvedilol Microsphere Formulation

Polymer	Category	Function in Formulation	Important Characteristic
Ethyl Cellulose	Non-biodegradable, hydrophobic	Primary matrix-former; retards drug release	Water-insoluble; pH-independent barrier; dissolves in DCM/ethanol
HPMC K100M	Semisynthetic, hydrophilic	Pore-former; channeling agent	Swells on hydration; creates aqueous drug-exit channels in EC wall
Eudragit RS100	Synthetic polymethacrylate	Sustained, pH-independent release coat	Quaternary ammonium groups; low permeability; blendable with RL100
Eudragit S100	Synthetic polymethacrylate	Enteric / pH-triggered release matrix	Insoluble below pH 7.0; dissolves in intestinal environment
Sodium Alginate	Natural anionic polysaccharide	Ionotropic gel bead matrix	Ca2+ crosslinking; amenable to floating bead design
Chitosan	Natural, deacetylated chitin	Mucoadhesive carrier polymer	Cationic surface binds negatively charged mucosal glycoproteins

EVALUATION OF MICROSPHERE FORMULATIONS

Yield and Drug Entrapment

How much of the raw material inputs ends up as usable microsphere product is measured as percentage yield: the collected, dried particle mass divided by the sum of drug and polymer masses weighed out at the start, multiplied by 100. Values below about 70 percent signal that a meaningful fraction was lost during processing — to the vessel walls, through the filter, or in washing — and that the method may not be economically viable at scale. Drug entrapment efficiency tells a related but distinct story: it asks what fraction of the drug that was put into the process actually ended up inside the particles rather than dissolving away into the aqueous continuous phase. Determining it requires physically breaking the microspheres open, extracting the drug from the crushed material into phosphate buffer pH 6.8 with 10 percent methanol as co-solvent, separating polymer debris by filtration, and then reading the concentration by UV absorbance at 241 nm.[33] Entrapment values above 75 percent are generally considered satisfactory for carvedilol systems.

Particle Size and Surface Morphology

Particle size influences both in vitro dissolution kinetics and the practical mechanics of filling the particles into capsules or blending them into tablets. Capsule filling machinery runs most reliably with powders whose particles sit between about 100 and 500 micrometres.[34] Optical microscopy fitted with a calibrated stage micrometer is the standard workhorse technique: measuring 100 to 150 individual particles across multiple fields of view and averaging the diameters provides a statistically defensible size figure for routine batch characterization. Scanning electron microscopy provides a qualitative complement, revealing the surface architecture — smooth and featureless surfaces suggest a dense, intact matrix whereas rough, cratered surfaces hint at rapid solvent evaporation, premature polymer precipitation, or residual pore structure that may accelerate drug release.

Powder Flow Characteristics

Before microspheres can be processed on industrial capsule-filling equipment, the powder must flow consistently from hoppers and through feed channels without bridging or segregating. Four complementary indices are normally measured: bulk density from the freely poured volume; tapped density from the volume after a standardized tap sequence; Carr's compressibility index, calculated as (tapped minus bulk density divided by tapped density) multiplied by 100; and the angle of repose of a cone poured under gravity through a funnel.[35] A compressibility index below 15 percent and a Hausner ratio (tapped density divided by bulk density) below 1.25 both indicate free-flowing behaviour; an angle of repose under 30 degrees points to the same conclusion.

In Vitro Release Testing and Mathematical Modelling

Release studies are run in a USP Type II (paddle) apparatus. The test begins with 900 mL of simulated gastric fluid (0.1 N hydrochloric acid, pH 1.2) to mimic the fasted stomach, with the paddle rotating at 100 revolutions per minute and the jacket holding the temperature at 37 plus or minus 0.5 degrees Celsius. After two hours the medium is replaced with phosphate buffer at pH 6.8 to simulate intestinal transit. Aliquots of five millilitres are withdrawn at one, two, four, six, eight, ten, and twelve hours; each withdrawal is immediately replaced with fresh medium at the same temperature to maintain constant volume and sink conditions. Drug concentration in each aliquot is measured spectrophotometrically at 241 nm.[36]

The cumulative release data are then fitted to four kinetic equations. Zero-order kinetics would mean that drug exits the matrix at the same rate regardless of how much remains inside — the ideal for a sustained-release design. First-order kinetics describe a decelerating release that is proportional to the remaining drug content. The Higuchi model attributes release to diffusion through the solid matrix, with cumulative release proportional to the square root of time. The Korsmeyer-Peppas power-law model is particularly informative: the exponent n discriminates between Fickian diffusion (n at or below 0.43, meaning diffusion alone drives release), anomalous or non-Fickian transport (n between 0.43 and 0.85, meaning both diffusion and polymer swelling contribute), and near-zero-order release (n above 0.85).[37] Formulations containing both ethyl cellulose and HPMC typically yield n values in the anomalous range, confirming that both the diffusion gradient and the HPMC swelling-and-dissolution mechanism are at work simultaneously.

Chemical Compatibility and Thermal Analysis

Confirming that the drug and excipients do not react chemically during manufacture or storage is a prerequisite before committing resources to full formulation development. Fourier-transform infrared spectroscopy achieves this by comparing the absorption spectra of the pure drug, the individual excipients, and physical mixtures prepared at the anticipated ratios.[38] Carvedilol's spectrum carries identifiable peaks associated with its N-H and C=O functional groups; as long as these remain at their characteristic wavenumbers without new peaks appearing or existing ones vanishing, chemical compatibility is confirmed. Differential scanning calorimetry complements FTIR by probing the physical state of the drug within the formulation: a sharp endothermic event at around 114 to 117 degrees Celsius marks the drug melting and confirms it is present in crystalline form. Broadening or disappearance of this event in the formulation thermogram indicates that the crystalline structure has been disrupted and the drug is dispersed within the polymer in an amorphous or molecularly dissolved state — a form that typically dissolves faster.[38]

Stability Under Accelerated Conditions

Pharmaceutical stability is evaluated under the accelerated conditions prescribed by ICH Q1A(R2): 40 degrees Celsius with 75 percent relative humidity, maintained in a programmable stability chamber for 90 days.[39] The best-performing batch is sealed in amber glass vials to exclude light. Samples withdrawn at the start and after 30, 60, and 90 days are retested for physical appearance, drug content, entrapment efficiency, and in vitro release profile. Absence of meaningful change across all these parameters over the 90-day window provides confidence that the formulation will retain its quality through a commercially realistic shelf life under tropical storage conditions.

KEY FINDINGS FROM RECENT RESEARCH (2016-2025)

Ethyl Cellulose-HPMC Matrix Microspheres

A consistent pattern has emerged across independent laboratories studying EC-HPMC carvedilol microspheres: as the EC content rises relative to the drug — moving from a 1:1.5 drug-to-polymer ratio toward 1:3.5 — particles grow larger, entrapment efficiency climbs from around 65 percent toward 90 percent, and the 12-hour release figure drops from roughly 80 percent to below 70 percent. The presence of HPMC at 10 to 20 percent of the total polymer fraction prevents the matrix from becoming so impermeable that release is unacceptably slow. Kinetic analysis reliably returns Korsmeyer-Peppas n values in the 0.45 to 0.65 range, confirming that both diffusion through the ethyl cellulose network and swelling-driven channel formation by the HPMC contribute to drug exit. This formulation architecture is now sufficiently well characterized to be considered a reproducible platform.

Floating and Gastroretentive Designs

The Gastroretentive microsphere literature for carvedilol has expanded considerably. Kumar et al. in 2022 prepared Eudragit RS100 and Cellulose Acetate hollow microballoons by emulsion solvent diffusion.[20] Particle diameters of 20 to 40 micrometres were obtained, and the buoyancy measurement — more than 80 percent of particles floating throughout a 12-hour test — was supported by drug release data fitting the Higuchi model, suggesting matrix diffusion as the operative mechanism. Sabale and colleagues in 2023 brought statistical rigour to alginate-pectin bead optimization, using a two-factor full factorial design to map how polymer and crosslinker concentrations influence floating lag time and drug release.[24] Their optimized beads floated immediately upon contacting the simulated gastric medium and maintained a steady, predictable release over the full 12-hour test, with no significant change after three months under accelerated storage conditions. Sharma and coworkers in 2023 took a slightly different engineering approach, formulating HPMC K100M-based floating matrix tablets and showing that the gel layer formed by HPMC swelling was the primary factor controlling both buoyancy duration and release rate; 98 percent release was achieved over 12 hours.[29]

pH-Responsive and Mucoadhesive Systems

Site-specific and mucoadhesive approaches have produced noteworthy results. The Eudragit S100 microspheres of Sahoo and colleagues in 2020 demonstrated a genuinely binary release behaviour: the drug was completely retained in pH 1.2 medium for the full two-hour gastric simulation phase, then released rapidly and completely when the medium was changed to pH 7.4.[30] This on-off characteristic is useful when gastric irritation or acid instability is a concern. On the mucoadhesive side, chitosan-based particles produced by Al-Kassas and collaborators in 2019 showed that the cationic polymer surface created strong enough adhesion to mucosal tissue models to prolong simulated residence time meaningfully, while drug release continued at a sustained rate for eight hours.[22]

Lipid Carriers and Transmucosal Routes

Work on lipid-based and transmucosal systems has pushed the performance benchmarks. Patel et al. in 2018 loaded carvedilol into solid lipid nanoparticles by hot homogenization followed by ultrasonication, capturing 91.43 percent of the drug in particles averaging 31.3 nanometres in diameter.[43] When the formulation was given to animals, the drug remained in the circulation for a mean of 23 hours and the total plasma exposure was more than double that produced by a plain aqueous solution of the drug — the most dramatic bioavailability improvement reported in the carvedilol microparticulate literature. El-Laithy and colleagues in 2022 built on the solid lipid nanoparticle concept by creating nanostructured lipid carriers that incorporated a liquid lipid fraction into the solid matrix, disrupting its crystalline order and creating additional capacity for drug loading.[40] The 150-nanometre particles showed a strongly negative zeta potential of minus 25 millivolts and reduced drug leakage during storage compared with conventional solid lipid nanoparticles. Eleftheriadis and coworkers in 2022 explored a radically different route by electrospinning carvedilol with HPMC E15 and PVA into ultrathin fibres intended for buccal application.[41] The spinning process converted the crystalline drug to an amorphous form, and the enormous surface-area-to-volume ratio of the fibres meant that dissolution on mucosal contact was essentially instantaneous, bypassing first-pass extraction entirely. Kaur and colleagues in 2020 arrived at a similar transmucosal goal through sublingual fast-dissolving films, which released 95 percent of the drug within five minutes — a format with obvious relevance for patients needing rapid blood pressure reduction.[42] Table 2 collects the key findings from these and other recent studies.

Table 2: Summary of Key Recent Studies on Carvedilol Microparticulate Systems (2016-2025)

Author, Year	System & Technique	Key Polymer(s)	Noteworthy Outcomes
Kumar et al., 2022[20]	Hollow floating microballoons; emulsion solvent diffusion	Eudragit RS100, Cellulose Acetate	EE >85%; particle size 20-40 um; >80% buoyancy maintained for 12 h; Higuchi kinetics confirmed
Sabale et al., 2023[24]	Floating beads; ionotropic gelation; 3(2) full factorial	Sodium alginate, Pectin, NaHCO3	Negligible floating lag time; steady release in simulated gastric fluid; stable after 90-day storage
Sharma et al., 2023[29]	Gastroretentive floating matrix tablets	HPMC K100M, NaHCO3	Buoyancy >12 h; 98% release achieved; gel-layer swelling identified as key release driver
El-Laithy et al., 2022[40]	Nanostructured lipid carriers (NLC)	Compritol 888 ATO, Miglyol 812	Size 150 nm; zeta potential -25 mV; drug leakage reduced; oral bioavailability improved

Eleftheriadis et al., 2022[41]	Electrospun nanofibers; buccal delivery	HPMC E15, PVA	Drug converted to amorphous state; rapid mucosal dissolution; complete first-pass bypass
Sahoo et al., 2020[30]	pH-sensitive microspheres; solvent evaporation	Eudragit S100	Zero release at pH 1.2 over 2 h; complete release at pH 7.4; gastric irritation avoided
Kaur et al., 2020[42]	Fast-dissolving sublingual polymeric films	HPMC E15, PVA, Propylene Glycol	95% drug dissolved within 5 min; appropriate for urgent hypertension management
Patel et al., 2018[43]	Solid lipid nanoparticles (SLN)	Glyceryl monostearate, Poloxamer 188	EE 91.43%; mean residence time 23 h in vivo; AUC more than doubled vs conventional dose
Nagarwal et al., 2018[31]	Floating in-situ gelling microsystem	Sodium alginate, Calcium carbonate	Immediate gelation on acid contact; buoyancy exceeded 12 h; promising sustained release
Patil et al., 2021[45]	Biphasic floating oral delivery system	HPMC K100M, Superdisintegrants	Dual immediate plus extended release over 12 h; effective haemodynamic control in models
Priyanka et al., 2021[44]	Semisolid matrix particulate system	Poloxamer 188, Gelucire 44/14	Release obeyed first-order model and Fickian diffusion; formulation physically stable at 40 C

FORMULATION CHALLENGES AND REGULATORY CONSIDERATIONS

Getting carvedilol into microspheres efficiently is harder than it might appear. The drug's high lipophilicity, which makes it easy to dissolve in the organic phase, also drives a thermodynamic equilibrium: some drug molecules always prefer the aqueous PVA continuous phase, especially as the organic solvent evaporates and the drug concentration in the organic droplet climbs. The fraction lost in this way directly reduces entrapment efficiency. Cooling the aqueous bath, keeping the PVA concentration at the minimum consistent with emulsion stability, and selecting polymers with strong affinity for the drug all help push the equilibrium in the desired direction.[46]

Dichloromethane, the workhorse solvent for ethyl cellulose dissolution and ESE processing, carries a regulatory burden. Classified as a Class 2 residual solvent by ICH Q3C with a permitted concentration of 600 ppm in finished pharmaceutical products, it must be removed by exhaustive drying — typically four hours of open stirring to allow surface evaporation followed by 24 hours under vacuum — before the batch can be considered safe.[47] Headspace gas chromatography should confirm compliance at the analytical stage for any formulation heading toward regulatory submission.

At the process level, maintaining a consistent particle size distribution from batch to batch is technically demanding. Stirrer speed, impeller geometry, temperature, and PVA concentration all interact to determine droplet size at the moment of emulsification, and small deviations in any of them can shift the product outside the 100 to 500 micrometre target range. Implementing process analytical technology tools — real-time turbidity or laser diffraction monitoring during the emulsification step — offers a practical route to catching and correcting drift before it compromises a full batch. Finally, establishing a credible in vitro-in vivo correlation remains an open problem because carvedilol's dissolution rate is strongly pH-dependent and no single dissolution medium captures the drug's behaviour across the entire gastrointestinal tract; appropriately designed pharmacokinetic studies in animal models or human volunteers are ultimately needed to bridge the gap.

CONCLUSIONS AND FUTURE PERSPECTIVES

The case for carvedilol microspheres rests on a straightforward clinical logic: the drug works well pharmacologically but is poorly served by conventional tablet formulations that subject patients to rapid absorption peaks, sub-therapeutic troughs, and multiple daily doses. The research literature assembled over the past decade has shown repeatedly that these problems are technically soluble through polymer-matrix microencapsulation. Ethyl cellulose-HPMC systems, the best-characterized of the available platforms, can be optimized to entrap more than three-quarters of the loaded drug, sustain its release across a 12 to 24-hour window, and survive accelerated storage conditions without significant degradation. Floating designs add the specific advantage of gastric retention, which suits carvedilol's pH-dependent absorption well. pH-sensitive Eudragit S100 matrices eliminate gastric exposure for patients with tolerability concerns. Chitosan microspheres and lipid nanocarriers push bioavailability improvements further, with in vivo data from solid lipid nanoparticle studies showing more than a doubling of systemic drug exposure compared to conventional dosing.

What the field now needs, in roughly decreasing order of urgency, is the following. First, a shift from empirical optimization to Quality by Design: systematic mapping of formulation and process variable spaces using designed experiments, followed by identification of the critical variables that most affect critical quality attributes, would produce design spaces that regulatory agencies can evaluate with confidence. Second, in vivo pharmacokinetic studies — properly powered, conducted in relevant animal models and ultimately in human volunteers — to establish whether the controlled release profiles observed in USP dissolution apparatus translate into proportionally flatter plasma concentration-time curves and improved bioavailability in living systems. Third, exploration of biodegradable PLGA-based microsphere platforms, which eliminate the residual solvent problem at its source and bring their own rich literature of release-rate tuning through co-polymer composition and molecular weight. Fourth, patient-centred formulation work that considers the practical realities of the population who will take these medicines: older individuals who may have dysphagia, polypharmacy-driven interactions, and variable gastric motility all need dosage forms that are designed with them specifically in mind, not adapted from platforms optimized for healthy volunteers. When these steps are taken, carvedilol microspheres will be positioned not just as a laboratory curiosity but as a genuine clinical advance in the management of one of the world's most prevalent chronic disease complexes.

REFERENCES

1. Frishman WH. Carvedilol. N Engl J Med. 1998;339(24):1759-65.
2. Ruffolo RR, Gellai M, Hieble JP, Willette RN, Nichols AJ. The pharmacology of carvedilol. Eur J Clin Pharmacol. 1990;38 Suppl 2:S82-8.
3. Morgan TO. Clinical pharmacokinetics and pharmacodynamics of carvedilol. Clin Pharmacokinet. 1994;26(5):335-46.
4. Kadam NR, Suvarna V. Microspheres: a brief review. Asian J Biomed Pharm Sci. 2015;5(47):13-9.
5. Alagusundaram M, Chetty CM, Umashankari K, Attuluri VB, Lavanya C, Ramkanth S. Microspheres as a novel drug delivery system: a review. Int J ChemTech Res. 2009;1(3):526-34.
6. Vyas SP, Khar RK. Targeted and controlled drug delivery: novel carrier systems. 1st ed. New Delhi: CBS Publishers; 2002. p. 417-54.
7. McTavish D, Campoli-Richards D, Sorkin EM. Carvedilol: a review of its pharmacodynamic and pharmacokinetic properties. Drugs. 1993;45(2):232-58.
8. Neugebauer G, Akpan W, von Mollendorff E, Neubert P, Reitz D. Pharmacokinetics and disposition of carvedilol in humans. J Cardiovasc Pharmacol. 1987;10 Suppl 11:S85-8.
9. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344(22):1651-8.
10. Tenero D, Boike S, Boyle D, Ilson B, Brozena S, Jorkasky D. Steady-state pharmacokinetics of carvedilol in patients with congestive heart failure. J Clin Pharmacol. 2000;40(8):844-53.
11. Bhatt DL, Bhatt S. Mechanisms and pharmacology of carvedilol in heart failure. Am J Cardiol. 2004;93(9 Suppl):3B-6B.

12. Ubaidulla U, Reddy MV, Ruckmani K, Khar RK, Ahmad FJ. Transdermal therapeutic system of carvedilol: effect of hydrophilic and hydrophobic matrix. AAPS PharmSciTech. 2007;8(1):E13-20.
13. Ramteke KH, Jadhav VB, Dhole SN. Microspheres as carriers used for novel drug delivery. IOSR J Pharm. 2012;2(4):44-8.
14. Vasir JK, Tambwekar K, Garg S. Bioadhesive microspheres as a controlled drug delivery system. Int J Pharm. 2003;255(1-2):13-32.
15. Singh BN, Kim KH. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. J Control Release. 2000;63(3):235-59.
16. Bardonnet PL, Faivre V, Pugh WJ, Piffaretti JC, Falson F. Gastroretentive dosage forms: overview and special case of Helicobacter pylori. J Control Release. 2006;111(1-2):1-18.
17. Sinha VR, Trehan A. Biodegradable microspheres for protein delivery. J Control Release. 2003;90(3):261-80.
18. Hafeli U. Physics and chemistry of polymeric magnetic targeted drug delivery systems. J Phys Condens Matter. 2006;18(38):S2947-60.
19. Freitas S, Merkle HP, Gander B. Microencapsulation by solvent extraction/evaporation: reviewing the state of the art. J Control Release. 2005;102(2):313-32.
20. Kumar A, Singh V, Sharma PK. Formulation and evaluation of floating microspheres of carvedilol using emulsion solvent diffusion method. AAPS PharmSciTech. 2022;23(4):102.
21. Pilcer G, Amighi K. Formulation strategy and use of excipients in pulmonary drug delivery. Int J Pharm. 2010;392(1-2):1-19.
22. Al-Kassas R, Bansal M, Shaw J. Controlled delivery of carvedilol via spray-dried chitosan microspheres. Int J Biol Macromol. 2019;131:456-65.
23. Gombotz WR, Wee SF. Protein release from alginate matrices. Adv Drug Deliv Rev. 2012;64 Suppl:194-205.
24. Sabale P, Sabale V, Patil S. Formulation and evaluation of carvedilol floating beads for chronotherapeutic management of hypertension. J Control Release. 2023;355:112-24.
25. Pavanetto F, Conti B, Genta I, Giunchedi P. Solvent evaporation, solvent extraction and spray drying for polylactide microsphere preparation. Int J Pharm. 1992;84(2):151-9.
26. Rowe RC, Sheskey PJ, Quinn ME. Handbook of pharmaceutical excipients. 6th ed. London: Pharmaceutical Press; 2009.
27. Bansal H, Kaur SP, Gupta AK. Microspheres: methods of preparation and applications. Int J Pharm Sci Rev Res. 2011;10(1):69-78.

28. Peppas NA, Bures P, Leobandung W, Ichikawa H. Hydrogels in pharmaceutical formulations. Eur J Pharm Biopharm. 2000;50(1):27-46.
29. Sharma V, Khanna K, Bansal M. Gastroretentive delivery systems of carvedilol: enhancement of solubility and absorption. Int J Pharm. 2023;634:122645.
30. Sahoo S, Chakraborti CK, Behera PK. Development of controlled release formulations based on carvedilol-carbopol-HPMC. J Adv Pharm Technol Res. 2020;11(3):77-82.
31. Nagarwal R, Kant S, Singh PN, Maiti P, Pandit JK. Novel floating in-situ gelling microsystems for carvedilol delivery. J Microencapsul. 2018;35(6):562-71.
32. Deng Z, Liu Z, Hu R, Li S. Polymeric micelles of carvedilol using Pluronic F127 for solubility enhancement. Nanomedicine. 2019;17:231-40.
33. Costa P, Lobo JM. Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2001;13(2):123-33.
34. Prasanth VV, Moy AC, Mathew ST, Mathapan R. Microspheres: an overview. Int J Res Pharm Biomed Sci. 2011;2(2):332-8.
35. Martin A, Bustamante P, Chun A. Physical pharmacy: physical chemical principles in pharmaceutical sciences. 4th ed. New Delhi: B.I. Waverly Pvt Ltd; 1994. p. 423-52.
36. United States Pharmacopeial Convention. United States Pharmacopeia (USP 43). Rockville: USP Convention; 2020.
37. Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm. 1983;15(1):25-35.
38. Indian Pharmacopoeia Commission. Indian Pharmacopoeia 2018. Ghaziabad: Ministry of Health and Family Welfare, Govt. of India; 2018.
39. ICH Q1A(R2). Stability testing of new drug substances and products. International Council for Harmonisation; 2003.
40. El-Laithy HM, El-Shaboury KM. Nanostructured lipid carriers of carvedilol: formulation, optimization and ex vivo permeation. Eur J Pharm Biopharm. 2022;173:88-99.
41. Eleftheriadis GK, Katsiotis CS, Bouropoulos N, Fatouros DG. Electrospun polymeric platforms for mucosal delivery of carvedilol. Drug Deliv Transl Res. 2022;12(8):1855-67.
42. Kaur G, Rana AC, Baibhav J. Fast-dissolving sublingual polymeric systems of carvedilol for rapid onset of action. Drug Dev Ind Pharm. 2020;46(5):780-91.
43. Patel R, Patel M. Solid lipid nanoparticles of carvedilol: formulation, in vitro and in vivo evaluation. J Liposome Res. 2018;28(1):65-74.

44. Priyanka S, Sivakumar T, Selvamuthukumar S. Sustained-release particulate systems of carvedilol using semisolid matrix technique. J Drug Deliv Sci Technol. 2021; 61:102148.
45. Patil SB, Sawant KK. Biphasic floating drug delivery systems of carvedilol for immediate and sustained release. Asian J Pharm Sci. 2021;16(2):215-25.
46. Liechty WB, Kryscio DR, Slaughter BV, Peppas NA. Polymers for drug delivery systems. Annu Rev Chem Biomol Eng. 2010; 1:149-73.
47. ICH Q3C(R8). Impurities: guideline for residual solvents. International Council for Harmonization; 2021.